Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model

  • Monoclon Antib Immunodiagn Immunother. 2020 Apr;39(2):37-44. doi: 10.1089/mab.2020.0001.
Yukinari Kato  1  2 ,  Yuji Ito  3 ,  Tomokazu Ohishi  4 ,  Manabu Kawada  4 ,  Takuro Nakamura  1 ,  Yusuke Sayama  1 ,  Masato Sano  1 ,  Teizo Asano  1 ,  Miyuki Yanaka  1 ,  Saki Okamoto  1 ,  Saori Handa  1 ,  Yu Komatsu  1 ,  Junko Takei  1 ,  Mika K Kaneko  1
Affiliations
  • 1. Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • 2. New Industry Creation Hatchery Center, Tohoku University, Sendai, Japan.
  • 3. Department of Chemistry and Bioscience, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan.
  • 4. Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, Shizuoka, Japan.
PMID: 32182186 DOI: 10.1089/mab.2020.0001
Abstract

Antibody-drug conjugates (ADCs), which consist of a monoclonal antibody (mAb), a linker, and a payload, can deliver a drug to Cancer tissues. We previously produced an anti-dog podoplanin (dPDPN) mAb, PMab-38, which reacts with dPDPN-expressing canine melanomas and squamous cell carcinomas (SCCs), but not with dPDPN-expressing canine type I alveolar cells or lymphatic endothelial cells, indicating that PMab-38 possesses Cancer specificity. In this study, we developed an ADC, P38B-DM1, using the mouse-canine chimeric anti-dPDPN antibody, P38B as the antibody, a peptide linker, and emtansine as the payload using the chemical conjugation by affinity peptide (CCAP) method. We investigated its cytotoxicity against dPDPN-overexpressed Chinese hamster ovary (CHO/dPDPN) cells in vitro and its antitumor activity using a mouse xenograft model of CHO/dPDPN cells. P38B-DM1 showed cytotoxicity to CHO/dPDPN cells in a dose-dependent manner in vitro. Furthermore, P38B-DM1 exhibited higher antitumor activity than P38B in the mouse xenograft model. These results suggest that P38B-DM1, developed using the CCAP method, is useful for antibody therapy against dPDPN-expressing canine SCCs and melanomas.

Keywords
antibody–drug conjugate; dog podoplanin; monoclonal antibody.
Products